Akari Therapeutics PLC 8-K Filing

Key Financial Figures

• $0.000000005 — Market LLC Ordinary Shares, par value $0.000000005 per share* N/A The Nasdaq Stock Mar
• $9 million — r, the Transactions total approximately $9 million in combined cash proceeds and liability
• $5 million — culated as the sum of (i) approximately $5 million in gross cash proceeds from a registere
• $4 million — the "Offerings") and (ii) approximately $4 million of non-cash reduction of outstanding no
• $0.3883 — ld in the Registered Direct Offering is $0.3883. In a concurrent Private Placement, p
• $0 — 13 ADSs at an exercise price per ADS of $0.00001, and (ii) accompanying Series G W
• $0.4041 — 3 ADSs, at a combined purchase price of $0.4041 per Pre-Funded Warrant and Series G War
• $5 m — erings are expected to be approximately $5 million, excluding any proceeds from any
• $0.00001 — nded Warrants have an exercise price of $0.00001 per ADS, will be immediately exercisabl
• $75,000 — -accountable expense allowance of up to $75,000. The Placement Agent or its designees w
• $0.4853875 — gent Warrants have an exercise price of $0.4853875 per ADS and will have a 5-year term fro

Filing Documents

• form8-k.htm (8-K) — 80KB
• ex5-1.htm (EX-5.1) — 128KB
• ex10-1.htm (EX-10.1) — 287KB
• ex10-2.htm (EX-10.2) — 305KB
• ex10-3.htm (EX-10.3) — 102KB
• ex10-4.htm (EX-10.4) — 123KB
• ex10-5.htm (EX-10.5) — 112KB
• ex10-6.htm (EX-10.6) — 125KB
• ex10-7.htm (EX-10.7) — 40KB
• ex10-8.htm (EX-10.8) — 130KB
• ex99-1.htm (EX-99.1) — 21KB
• ex5-1_001.jpg (GRAPHIC) — 25KB
• ex99-1_001.jpg (GRAPHIC) — 13KB
• 0001493152-25-028075.txt ( ) — 2005KB
• aktx-20251216.xsd (EX-101.SCH) — 4KB
• aktx-20251216_def.xml (EX-101.DEF) — 26KB
• aktx-20251216_lab.xml (EX-101.LAB) — 36KB
• aktx-20251216_pre.xml (EX-101.PRE) — 25KB
• form8-k_htm.xml (XML) — 6KB

02

Item 1.02. Termination of a Material Definitive Agreement. The description of the 2026 Notes and Exchange Agreement described in Item 1.01 is hereby incorporated by reference in this Item 1.02. At the closing of the Exchange, all 2026 Notes will be retired, following which no such notes remain issued or outstanding. Item 3.02. Unregistered Sales of Equity Securities. The information under Item 1.01 of this Current Report on Form 8-K regarding the Warrants, Placement Agent Warrants, the Note Exchange Warrants and the ADSs and Ordinary Shares issuable upon exercise of the Warrants, Placement Agent Warrants and Note Exchange Warrants is incorporated herein by reference.

01

Item 7.01 Regulation FD Disclosure The Company previously announced the Offering in a press release issued on December 16, 2025. A copy of such press release is furnished as exhibit 99.1 to this Current Report on Form 8-K. The information set forth in this Item 7.01 of this Current Report on Form 8-K and in the attached Exhibit 99.1 are deemed to be "furnished" and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section. The information set forth in Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1, shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act, regardless of any general incorporation language in such filing. Forward Looking Statements This Report on Form 8-K contains statements which constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward looking statements are based upon the Company's present intent, beliefs or expectations, but forward looking statements are not guaranteed to occur and may not occur for various reasons, including some reasons which are beyond the Company's control. For example, this Report states that the Offerings are expected to close on or about December 17, 2025. In fact, the closing of the Offerings are subject to various conditions and contingencies as are customary in securities purchase agreements in the United States. If these conditions are not satisfied or the specified contingencies do not occur, this Offerings may not close. For this reason, among others, you should not place undue reliance upon the Company's forward looking statements. Except as required by law, the Company undertakes no obligation to revise or update any forward looking statements in order to reflect any event or circumstance that may arise after the

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Akari Therapeutics, Plc Date: December 17, 2025 By: /s/ Kameel Farag Name: Kameel Farag Title: Interim Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR